| Literature DB >> 15275710 |
M Carmen Hernandez1, Susan J Knox.
Abstract
The radiobiology of radioimmunotherapy is an important determinant of both the toxicity and the efficacy associated with the treatment of B-cell non-Hodgkin's lymphoma with radiolabeled anti-CD20 monoclonal antibodies. The properties of the target, CD20, and the mechanisms of action of both the monoclonal antibodies and the associated exponentially decreasing low-dose-rate radiotherapy are described. The radiation dose and dose-rate effects are discussed and related to both the tumor responses and normal organ toxicity. Finally, the use of either unlabeled or radiolabeled anti-CD20 monoclonal antibodies as a component of combined modality therapy (including the sequential or concurrent use of sensitizers) and future directions of the field are discussed.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15275710 DOI： 10.1016/j.ijrobp.2004.02.065
Source DB: PubMed Journal: Int J Radiat Oncol Biol Phys ISSN： 0360-3016 Impact factor: 7.038